Skip to main content

Table 2 Results of univariate analysis of time to CR in fertility-sparing treatment of AEH and early EC

From: Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients

 

Time to CR

OR (95%CI)

P-value

Age (years)

-0.1 (-0.3, 0.1)

0.316

BMI (kg/m2)

0.2 (-0.0, 0.3)

0.054

HOMA-IR

0.1 (-0.1, 0.4)

0.377

FBG (mmol/L)

1.6 (0.6, 2.5)

0.020

Serum insulin (μU/mL)

0.0 (-0.0, 0.1)

0.608

HDL (mmol/L)

0.2 (-0.2, 0.5)

0.347

Triglyceride (mmol/L)

0.4 (-0.1, 0.6)

0.158

IR

0.3 (-1.2, 1.8)

0.657

DM

0.1 (-1.7, 1.9)

0.932

HBP

0.2 (-2.7, 3.0)

0.914

MetS

3.0 (1.1, 5.0)

0.003

PCOS

2.0 (0.5, 3.4)

0.009

Gestation

-0.7 (-2.3, 0.8)

0.355

Parity

-1.6 (-3.6, 0.4)

0.118

Infertility

0.1 (-1.4, 1.6)

0.885

Histological type

1.0 (-0.5, 2.5)

0.197

Metformin

-0.7 (-2.2, 0.8)

0.343

MPA250mg

0.7 (-0.8, 2.2)

0.363

MPA500mg

-0.1 (-1.9, 1.8)

0.923

MA

0.9 (-1.1, 2.9)

0.380

GnRH-a

-0.9 (-3.2, 1.3)

0.418

  1. CR Complete remission, BMI Body mass index, HOMA-IR Homeostasis model assessment of insulin resistance-insulin resistance, FBG Fasting blood glucose, HDL High-density lipoprotein, IR Insulin resistance, DM Diabetes, HBP High blood pressure, MetS Metabolic syndrome, PCOS Polycystic ovarian syndrome, MPA Oral medroxyprogesterone acetate, MA Oral megestrol acetate
Back to article page

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us